On Sept. 15, 2017, the U.S. Centers for Disease Control and Prevention (CDC) published updated GamaSTAN S/D prescribing information with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications.

These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma.